Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
2
×
biogen
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
clinical trials
detroit blog main
detroit top stories
eli lilly
gene therapy
glaxosmithkline
indiana blog main
indiana top stories
johnson & johnson
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
satsuma pharmaceuticals
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
zolgensma
2
×
10x genomics
adalimumab (humira)
What
bio
2
×
news
roundup
approval
august
biogen’s
biopharmaceutical
biotech
busy
companies
convo
days
decisions
devices
drug
drugs
earlier
failures
fda
legacy
littered
nash
new
nods
opioid
past
price
regulatory
remains
road
sarepta’s
seven
shkreli’s
slow
strategy
stumble
suits
talk
tends
won
Language
unset
Current search:
zolgensma
×
bio
×
abbvie
×
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More